Advances in the Management of Pediatric Low-Grade Glioma (pLGG): A Focus on Optimizing Treatment Strategies

Panelists discuss pediatric low-grade glioma as a chronic, highly variable disease in which treatment decisions prioritize long-term quality of life and minimizing morbidity despite generally excellent survival outcomes.

Panelists highlight how advances in molecular profiling—particularly involving the MAPK pathway and BRAF alterations—are transforming pediatric low-grade glioma treatment by enabling targeted therapies that improve quality of life while introducing new considerations around prognosis and long-term effects.

Learn how MAPK, BRAF fusions and V600E mutations shape pediatric low‑grade glioma treatment, targeted drugs, side effects and long‑term unknowns.

Explore how pediatric low-grade glioma care weighs function, vision, NF1 status, and family goals—often choosing watchful waiting over treatment despite MRI growth.

Pediatric low‑grade glioma care weighs observation versus treatment, focusing on child function, vision changes, MRI trends, family goals, and NF1 status.

Pediatric low-grade glioma care focuses on symptoms and function over tiny MRI size changes, using baseline scans, time, and multidisciplinary monitoring.

Experts weigh PLGG treatment choices, balancing chemo and MEK inhibitors, guided by vision decline, symptoms, tumor growth, and family logistics.

Learn how clinicians weigh symptoms, MRI changes and family goals to decide when a child’s tumor needs treatment—beyond simple size cutoffs.

Experts explain how pediatric low‑grade glioma MRIs are read: why T2/FLAIR matters more than contrast, and how to discuss RAVNO with families.

Experts debate how to define true radiographic progression in pediatric optic pathway tumors, using 25% growth and vision risk to guide therapy.

Experts weigh oral targeted therapies for pediatric low-grade glioma, outlining MEK inhibitor risks, tovorafenib growth suppression, and factors shaping treatment timing decisions.

Experts weigh MEK inhibitors vs tovorafenib, highlighting rash, cardiac monitoring, lab changes, and growth suppression to guide treatment timing.